ACE Report Cover
Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
METABOLIC DISORDERS
Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis .
High Impact
This study has been identified as potentially high impact. OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself. Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone. This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.

Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis

N Engl J Med. 2007 Nov 15;357(20):2028-39

428 patients with glucocorticoid-induced osteoporosis were randomised to receive one of two treatments. The first group received a treatment of 20 μg teriparatide daily while the second group received a 10 mg alendronate treatment. The primary outcome was change in bone mineral density at the lumbar spine from baseline to the 18-month follow-up. Results indicated that bone mineral density increased more in patients from the teriparatide group compared to the those in the alendronate group.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis. ACE Report. 2013;2(7):167. Available from: https://myorthoevidence.com/AceReport/Show/teriparatide-increases-bmd-in-patients-with-glucocorticoid-induced-osteoporosis

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report